Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Moskowitz
    Moskowitz
  3. Zelenetz
    Zelenetz
  4. Horwitz
    Horwitz
  5. Schoder
    Schoder
  6. Stein
    Stein
  7. Trippett
    Trippett
  8. Abdel-Wahab
    Abdel-Wahab
  9. Grewal
    Grewal
  10. Hamlin
    Hamlin

Groups

  1. Center for Hematologic Malignancies (30)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Lymphoma (13)
  5. Executive Committee, Center for Hematologic Malignancies (6)
  6. Bone Marrow Transplant (5)
  7. Pediatric Leukemia (5)
  8. Survivorship Research (5)
  9. Adult Leukemia (4)
  10. Myeloma (4)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "Lancet Oncology"
Formats
  1. Journal Article (28)
  2. Correspondence (1)
  3. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (30)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Lymphoma (13)
  5. Executive Committee, Center for Hematologic Malignancies (6)
  6. Bone Marrow Transplant (5)

More Groups

People
  1. Anas Younes (4)
  2. Matthew Matasar (4)
  3. Alison Moskowitz (3)
  4. Andrew Zelenetz (3)
  5. Sergio Giralt (3)
  6. Carl Landgren (2)

More People

Years
  1. 2022 (3)
  2. 2021 (2)
  3. 2020 (4)
  4. 2019 (1)
  5. 2018 (3)
  6. 2017 (2)

More Years

Publications
  1. Lancet Oncology (30)

Results (30)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: A multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Journal Article

    Pagel, J. M.; Soumerai, J. D.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A.; Salman, H.; Kenkre, V. P.; Iasonos, A.; Llorin-Sangalang, J.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): A single-arm, phase 1b and randomised, phase 2 trial
    Journal Article

    DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos, P.; Wei, A. H.; de Botton, S.; Zeidan, A. M.; Fathi, A. T.; Kantarjian, H. M.; Bennett, J. M.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial
    Journal Article

    Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial
    Journal Article

    Morschhauser, F.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Batlevi, C. L.; Campbell, P.; Ribrag, V.; Damaj, G. L.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study
    Journal Article

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N.; Lendvai, N.; Sborov, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): A multicentre phase 1-2 study
    Journal Article

    Geoerger, B.; Zwaan, C. M.; Marshall, L. V.; Michon, J.; Bourdeaut, F.; Casanova, M.; Corradini, N.; Rossato, G.; Farid-Kapadia, M.; Shemesh, C. S.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): A Children's Oncology Group prospective study
    Journal Article

    Spunt, S. L.; Million, L.; Chi, Y. Y.; Anderson, J.; Tian, J.; Hibbitts, E.; Coffin, C.; McCarville, M. B.; Randall, R. L.; Parham, D. M.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders
    Guidelines

    Hillengass, J.; Usmani, S.; Rajkumar, S. V.; Durie, B. G. M.; Mateos, M. V.; Lonial, S.; Joao, C.; Anderson, K. C.; García-Sanz, R.; Riva, E.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save